click below
click below
Normal Size Small Size show me how
Hemostasis
| Class | Drugs | Mechanism | Adverse effects | Indications |
|---|---|---|---|---|
| Anti-coagulants - inhibit active factors | Heparin | Very acidic (antidote is basic) - very quick acting (IV admin) - activated ATIII (1000X) and inactivates factor Xa | (HIT) heparin-induced thrombocytopenia, osteoporosis, allergic, | pregnancy |
| Anti-coagulants - inhibit factor synthesis | Warfarin (oral) | Vit K antagonist (can't get reduced/recycled) - a week to start and a week to stop - CYP2C9 slow metab VKORC fast metab | bleeding, hypersensitivity, TONS of drug interactions | pregnancy, liver or kidney disease (metab/excrete)CYP2C9 |
| Anti-coagulants - direct thrombin inhibitors | Hirudin | Inhibits fibrin activation, | (blank) | (blank) |
| Anti-coagulants - inhibit active factors | LMW Heparin | LMWHeparin inhibits Xa, Subcut admin, Don't have to monitor levels like others | (blank) | (blank) |
| Anti-coagulants - inhibit active factors | Fundaparinux | Inhibits Xa, Not assoc with HIT or Heparin induced osteoporosis | (blank) | (blank) |
| Anti-coagulants - direct thrombin inhibitors | AT III | (blank) | (blank) | used for hereditary ATIII deficiency |
| Anti platelet - prevent aggregation | ticlopidine, clopidogrel, dipyridamole | Inhibits ADP-induced aggregation, irreversible, decreased adhesion. (ticlopidine, clopidogrel bind ADP receptor, dipyridamole inhibits ADP uptake) | statistically significant (but not really clinically significant) elevation in lever fxn, (ticlopidine - TPP, aplastic anemia), bleeding | (dipyridamole) post-op clot prevention - can replace exercise in heart stress test (vasodilator) |
| Anti platelet - prevent adhesion | Abciximab(monoclonal Ab), tirofiban (peptide), eptifibatide (synthetic non-peptide- oral bioavailability) | block IIa/IIIb receptor - no platelet binding. Abciximab has shortest half-life (10min) and highest affinity (longest for platelet fxn to return to normal), tirofiban next, eptifibatide next | bleeding | (blank) |
| Anti-Platelet - COX inhibitors | Aspirin | Irreversibly acetylates COX - inhibits platelet-induced vasoconstriction | (blank) | (blank) |
| Thrombolytic - main | Streptokinase, alteplase (synthetic streptokinase) | activates plasminogen to plasmin. (streptokinase is antigenic so can only be used once or twice) - short half life | bleeding - can be reversed with aminocaproic acid | (blank) |
| Thrombolytic - others | anistreplase, urokinase | activates plasminogen | bleeding | (blank) |
| Anti-fibrinolytic (prevent clot dissolution) | Epsilon-Aminocaproid acid | activates plasminogen to plasmin, then sits in active site of plasmin | (blank) | (blank) |
| Drug-eluting stent | sirolimus, paclitaxel | Don't prevent clots, just inhibit growth of endothelium over stents and forming next clots. | Doesn't seem to work quite as well as we think | (blank) |
| Recombinant protein C | recombinant protein C | Inactivated Va and IIIa to prevent bleeding | bleeding | sepsis |